Analysts Offer Predictions for Alzamend Neuro Q1 Earnings

Alzamend Neuro, Inc. (NASDAQ:ALZN) – Stock analysts at Ascendiant Capital Markets issued their Q1 2028 earnings per share (EPS) estimates for shares of Alzamend Neuro in a report released on Tuesday, August 18th. Ascendiant Capital Markets analyst E. Woo expects that the company will post earnings per share of ($0.22) for the quarter. The consensus estimate for Alzamend Neuro’s current full-year earnings is ($2.60) per share. Ascendiant Capital Markets also issued estimates for Alzamend Neuro’s Q2 2028 earnings at ($0.22) EPS, Q3 2028 earnings at ($0.22) EPS, Q4 2028 earnings at ($0.21) EPS and FY2028 earnings at ($0.87) EPS.

Separately, Weiss Ratings downgraded shares of Alzamend Neuro from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday, August 17th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $28.00.

Alzamend Neuro Stock Performance

Shares of NASDAQ ALZN opened at $1.55 on Monday. Alzamend Neuro has a fifty-two week low of $0.84 and a fifty-two week high of $2.68. The company has a market cap of $7.42 million, a PE ratio of -0.53 and a beta of 0.16. The business has a 50-day simple moving average of $1.32 and a two-hundred day simple moving average of $1.38.

Alzamend Neuro (NASDAQ:ALZN) last announced its earnings results on Wednesday, July 22nd. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.07).

Institutional Trading of Alzamend Neuro

A hedge fund recently raised its stake in Alzamend Neuro stock. DRW Securities LLC raised its position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) by 27.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 116,319 shares of the company’s stock after purchasing an additional 25,074 shares during the quarter. DRW Securities LLC owned 3.06% of Alzamend Neuro worth $212,000 at the end of the most recent reporting period. 49.61% of the stock is owned by hedge funds and other institutional investors.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.